UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2025
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of registrant’s name into English)
Via
Olgettina No. 58
20132
Milan, Italy
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Other
Events
On
December 30, 2024, the Company and AGC Biologics S.p.A. (“AGC”) entered into the Second Amendment to the Development and
Master Services Agreement, effective as of March 6, 2019, and as amended as of March 5, 2024. In conjunction with entry into the Second
Amendment, the Company also entered into Work Statement No. 1 for AGC to manufacture, test, and release certain of the Company’s
cell therapy products and provide for a dedicated GMP suite. On August 1, 2025, the Company notified AGC of its intent to terminate Work
Statement No. 01, pursuant to Section 4.1 of the Second Amendment to the Development and Master Services Agreement, which would eliminate
the Company’s commitment to a dedicated suite effective August 1, 2026, but will allow AGC to continue to manufacture certain drug
products for the Company in shared suites.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
GENENTA
SCIENCE S.P.A. |
| |
|
|
| |
By: |
/s/
Richard B. Slansky |
| |
Name:
|
Richard B. Slansky |
| |
Title: |
Chief
Financial Officer |
Dated:
August 1, 2025
